{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:02:24Z","timestamp":1788469344513,"version":"build-2803163510"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aim of this study was to evaluate the transcriptome of peripheral blood mononuclear cells (PBMCs) derived from patients affected by psoriasis (PSO) and psoriatic arthritis (PSA) following treatment with guselkumab, an interleukin (IL)-23 inhibitor.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>mRNA was extracted by PBMCs, before and after 24 weeks of treatment with guselkumab, and RNA sequencing was performed in paired-end mode by Illumina technology using the Novaseq6000 platform. log2FoldChange &amp;gt; 1 and <jats:italic>p<\/jats:italic><jats:sub>adj<\/jats:sub> &amp;lt; 0.05 were the established cutoff to discriminate genes differentially expressed between pre- and post-therapy. For annotation and predictive enrichment analysis of deregulated genes in biological pathways, RStudio was used, and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases were queried. Cytoscape_v3.10.3 was used for the development of the network between deregulated genes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Six na\u00efve active patients with PSO and PSA, diagnosed with a duration &amp;lt;2 years, were assessed before and after 24 weeks of treatment with guselkumab. Performing the quality check and filtering analyses, we found 506 transcripts deregulated between pre- and post-therapy, of which 129 were upregulated and 377 were downregulated. The most upregulated mRNAs included SYTL3, CPT1A, TMEM208, GINS4, and TNFRSF13C. The most downregulated mRNAs included CCR2, TPT1, MYCBP, CMPK1, and TMEM65. Enrichment with the GO database showed the following main deregulated processes: \u201cprotein targeting\u201d, \u201cthe establishment of protein localization to membrane\u201d, and \u201cmetabolism of fatty acids\u201d. The analysis of the main macro-process showed the several pathways deregulated after therapy, including signaling related to ethanol metabolism, thermogenesis, oxidative phosphorylation, and fatty acid metabolism (KEGG).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our findings may give further insights into manipulated mechanistic pathways by IL-23 inhibition in patients with PSO and PSA.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1672667","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T05:34:54Z","timestamp":1756791294000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessment of gene signatures following the inhibition of IL-23: a study to evaluate the mechanistic effects behind the clinical efficacy of guselkumab in patients with psoriatic arthritis"],"prefix":"10.3389","volume":"16","author":[{"given":"Mirco","family":"Mastrangelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Ruscitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfredo","family":"Bruni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Lucantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"De Berardinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Barile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Fargnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","first-page":"941","DOI":"10.3899\/jrheum.200051","article-title":"Psoriatic syndrome or psoriatic disease","volume":"47","author":"Scarpa","year":"2020","journal-title":"J Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00776-6","article-title":"Psoriatic arthritis from a mechanistic perspective","volume":"18","author":"Schett","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-024-08991-7","article-title":"The immunology of psoriasis-current concepts in pathogenesis","volume":"66","author":"Sieminska","year":"2024","journal-title":"Clin Rev Allergy Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1229516","article-title":"Cytokine profile characterization of na\u00efve patients with psoriasis and psoriatic arthritis: implications for a pathogenic disease continuum","volume":"14","author":"Ruscitti","year":"2023","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152574","article-title":"The role of the gastrointestinal microbiome on rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and reactive arthritis: A systematic review","volume":"70","author":"Ng","year":"2025","journal-title":"Semin Arthritis Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01038-9","article-title":"Predominant ligament-centric soft-tissue involvement differentiates axial psoriatic arthritis from ankylosing spondylitis","volume":"19","author":"McGonagle","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218186","article-title":"IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors","volume":"80","author":"Nerviani","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00578-0","article-title":"Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: A comprehensive review","volume":"22","author":"Yang","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/msc.1694","article-title":"The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis","author":"Fragoulis","year":"2022","journal-title":"Musculoskeletal Care"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078644","article-title":"Comparison of RNA-Seq and microarray in transcriptome profiling of activated T cells","volume":"9","author":"Zhao","year":"2014","journal-title":"PloS One"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-13-629","article-title":"RNA-seq and microarray complement each other in transcriptome profiling","volume":"13","author":"Kogenaru","year":"2012","journal-title":"BMC Genomics"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.008","article-title":"Diagnosis and classification of psoriasis","volume":"13","author":"Raychaudhuri","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B18","unstructured":""},{"key":"B19","unstructured":""},{"key":"B20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btu684","article-title":"DOSE: an R\/bioconductor package for disease ontology semantic and enrichmentanalysis","volume":"31","author":"Yu","year":"2015","journal-title":"Bioinformatics"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1346757","article-title":"From PsO to PsA: the role of TRM and Tregs in psoriatic disease, a systematic review of the literature","volume":"11","author":"Lob\u00e3o","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15865","article-title":"Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis Group","volume":"35","author":"Rocamora","year":"2022","journal-title":"Dermatol Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.679027","article-title":"SYTL3-SLC22A3 single-nucleotide polymorphisms and gene-gene\/environment interactions on the risk of hyperlipidemia","volume":"12","author":"Zheng","year":"2021","journal-title":"Front Genet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/art.42010","article-title":"Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two\u2009Years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis","volume":"74","author":"McInnes","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2019.04.067","article-title":"Rapamycin modulate treg\/th17 balance via regulating metabolic pathways: A study in mice","volume":"51","author":"Zhang","year":"2019","journal-title":"Transplant Proc"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.8.4314","article-title":"BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases","volume":"169","author":"Roschke","year":"2002","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103207","article-title":"Analysis of rheumatoid- vs psoriatic arthritis synovial fluid reveals differential macrophage (CCR2) and T helper subsets (STAT3\/4 and FOXP3) activation","volume":"21","author":"Caso","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058196","article-title":"IL-23 induces atopic dermatitis-like inflammation instead of psoriasis-like inflammation in CCR2-deficient mice","volume":"8","author":"Bromley","year":"2013","journal-title":"PloS One"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e38819","article-title":"The multifaceted potential of TPT1 as biomarker and therapeutic target","volume":"10","author":"Miao","year":"2024","journal-title":"Heliyon"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11589","article-title":"Guselkumab modulates differentially expressed genes in blood of patients with psoriatic arthritis: results from two phase 3, randomized, placebo-controlled trials","volume":"5","author":"Siebert","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09595.x","article-title":"Psoriasis and alcohol: is cutaneous ethanol one of the missing links","volume":"162","author":"Farkas","year":"2010","journal-title":"Br J Dermatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.835760","article-title":"Combined single cell transcriptome and surface epitope profiling identifies potential biomarkers of psoriatic arthritis and facilitates diagnosis via machine learning","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600810","article-title":"Inhibiting oxidative phosphorylation in vivo restrains th17 effector responses and ameliorates murine colitis","volume":"198","author":"Franchi","year":"2017","journal-title":"J Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11306-021-01805-3","article-title":"Serum metabolic fingerprinting of psoriasis and psoriatic arthritis patients using solid-phase microextraction-liquid chromatography-high-resolution mass spectrometry","volume":"17","author":"Looby","year":"2021","journal-title":"Metabolomics"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1179877","article-title":"Single-cell transcriptomic landscape of immunometabolism reveals intervention candidates of ascorbate and aldarate metabolism, fatty-acid degradation and PUFA metabolism of T-cell subsets in healthy controls, psoriasis and psoriatic arthritis","volume":"14","author":"Peng","year":"2023","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0258812","article-title":"The impact of the Th17:Treg axis on the IgA-Biome across the glycemic spectrum","volume":"16","author":"Essigmann","year":"2021","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/1348-0421.12560","article-title":"Interleukin-17 family cytokines in protective immunity against infections: role of hematopoietic cell-derived and non-hematopoietic cell-derived interleukin-17s","volume":"62","author":"Matsuzaki","year":"2018","journal-title":"Microbiol Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1672667\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T05:34:55Z","timestamp":1756791295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1672667\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2025.1672667"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1672667","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"article-number":"1672667"}}